questionsmedicales.fr
Acides aminés, peptides et protéines
Peptides
Hormones peptidiques
Peptides natriurétiques
Peptides natriurétiques : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Insuffisance cardiaque
Peptides natriurétiques
Essoufflement
Palpitations
Valeurs normales
Peptides natriurétiques
Insuffisance cardiaque
Surcharge volumique
Symptômes
5
Essoufflement
Douleurs thoraciques
Biomarqueurs
Insuffisance cardiaque
Personnes âgées
Diagnostic
Différences sexuelles
Diagnostic
Prévention
5
Mode de vie sain
Hypertension
Contrôles médicaux
Problèmes cardiaques
Traitements
5
Diurétiques
Inhibiteurs de l'ACE
Analogues
Insuffisance cardiaque
Diurétiques
Volume sanguin
Hypotension
Effets secondaires
Complications
5
Insuffisance cardiaque
Arythmie
Insuffisance rénale
Problèmes cardiaques
Douleurs thoraciques
Syncopes
Facteurs de risque
5
Tabagisme
Maladies cardiaques
Âge
Insuffisance cardiaque
Stress chronique
Hypertension
Inactivité physique
Maladies cardiovasculaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Peptides natriurétiques : Questions médicales les plus fréquentes",
"headline": "Peptides natriurétiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Peptides natriurétiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-19",
"dateModified": "2025-02-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Peptides natriurétiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hormones peptidiques",
"url": "https://questionsmedicales.fr/mesh/D036361",
"about": {
"@type": "MedicalCondition",
"name": "Hormones peptidiques",
"code": {
"@type": "MedicalCode",
"code": "D036361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.644.548"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteur atrial natriurétique",
"alternateName": "Atrial Natriuretic Factor",
"url": "https://questionsmedicales.fr/mesh/D009320",
"about": {
"@type": "MedicalCondition",
"name": "Facteur atrial natriurétique",
"code": {
"@type": "MedicalCode",
"code": "D009320",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.644.548.585.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Peptide natriurétique de type C",
"alternateName": "Natriuretic Peptide, C-Type",
"url": "https://questionsmedicales.fr/mesh/D020098",
"about": {
"@type": "MedicalCondition",
"name": "Peptide natriurétique de type C",
"code": {
"@type": "MedicalCode",
"code": "D020098",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.644.548.585.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Peptides natriurétiques",
"alternateName": "Natriuretic Peptides",
"code": {
"@type": "MedicalCode",
"code": "D045265",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jens P Goetze",
"url": "https://questionsmedicales.fr/author/Jens%20P%20Goetze",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Biochemistry, Rigshospitalet University Hospital, Copenhagen, Denmark."
}
},
{
"@type": "Person",
"name": "Speranza Rubattu",
"url": "https://questionsmedicales.fr/author/Speranza%20Rubattu",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. speranzadonatella.rubattu@uniroma1.it."
}
},
{
"@type": "Person",
"name": "John C Burnett",
"url": "https://questionsmedicales.fr/author/John%20C%20Burnett",
"affiliation": {
"@type": "Organization",
"name": "Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA. Electronic address: burnett.john@mayo.edu."
}
},
{
"@type": "Person",
"name": "Naoto Minamino",
"url": "https://questionsmedicales.fr/author/Naoto%20Minamino",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Suita, Japan."
}
},
{
"@type": "Person",
"name": "Katherine N Bachmann",
"url": "https://questionsmedicales.fr/author/Katherine%20N%20Bachmann",
"affiliation": {
"@type": "Organization",
"name": "Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G)."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies.",
"datePublished": "2023-06-23",
"url": "https://questionsmedicales.fr/article/37356719",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jbc.2023.104956"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using genetics to explore complement C5 as a druggable protein in periodontitis.",
"datePublished": "2024-10-08",
"url": "https://questionsmedicales.fr/article/39439802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2024.1407431"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5.",
"datePublished": "2023-04-20",
"url": "https://questionsmedicales.fr/article/37079521",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0284502"
}
},
{
"@type": "ScholarlyArticle",
"name": "Soluble MAC is primarily released from MAC-resistant bacteria that potently convert complement component C5.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947526",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7554/eLife.77503"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.",
"datePublished": "2024-07-15",
"url": "https://questionsmedicales.fr/article/39009967",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12882-024-03662-3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Peptides",
"item": "https://questionsmedicales.fr/mesh/D010455"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hormones peptidiques",
"item": "https://questionsmedicales.fr/mesh/D036361"
},
{
"@type": "ListItem",
"position": 5,
"name": "Peptides natriurétiques",
"item": "https://questionsmedicales.fr/mesh/D045265"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Peptides natriurétiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Peptides natriurétiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Peptides natriurétiques",
"description": "Comment diagnostiquer une insuffisance cardiaque ?\nQuels tests mesurent les peptides natriurétiques ?\nQuels symptômes indiquent un test de peptides natriurétiques ?\nQuelle est la valeur normale des peptides natriurétiques ?\nComment interpréter un taux élevé de BNP ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Peptides natriurétiques",
"description": "Quels sont les symptômes des peptides natriurétiques élevés ?\nLes peptides natriurétiques causent-ils des symptômes ?\nComment les symptômes varient-ils selon l'âge ?\nLes symptômes sont-ils différents chez les hommes et les femmes ?\nQuels signes cliniques sont associés aux peptides natriurétiques ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Peptides natriurétiques",
"description": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?\nL'alimentation influence-t-elle les niveaux de peptides natriurétiques ?\nL'exercice régulier aide-t-il à prévenir des niveaux élevés ?\nLe stress affecte-t-il les peptides natriurétiques ?\nLes contrôles médicaux réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Peptides natriurétiques",
"description": "Quels traitements sont basés sur les peptides natriurétiques ?\nLes peptides natriurétiques sont-ils utilisés en thérapie ?\nComment les diurétiques agissent-ils sur les peptides natriurétiques ?\nLes traitements affectent-ils les niveaux de BNP ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Peptides natriurétiques",
"description": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?\nLes peptides natriurétiques sont-ils liés à des maladies rénales ?\nComment les complications cardiovasculaires se manifestent-elles ?\nLes complications sont-elles réversibles ?\nQuels facteurs aggravent les complications liées aux peptides natriurétiques ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Peptides natriurétiques",
"description": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?\nLe tabagisme influence-t-il les niveaux de peptides natriurétiques ?\nL'âge est-il un facteur de risque ?\nLe stress chronique influence-t-il la santé cardiaque ?\nL'inactivité physique est-elle un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D045265?mesh_terms=Complement+C5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une insuffisance cardiaque ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur des examens cliniques, échographies et dosages de peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "Quels tests mesurent les peptides natriurétiques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sanguins mesurent le BNP ou le NT-proBNP pour évaluer la fonction cardiaque."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un test de peptides natriurétiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Essoufflement, fatigue, œdème et palpitations peuvent justifier un test de peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "Quelle est la valeur normale des peptides natriurétiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les valeurs normales varient, mais un BNP < 100 pg/ml est souvent considéré comme normal."
}
},
{
"@type": "Question",
"name": "Comment interpréter un taux élevé de BNP ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé de BNP indique souvent une insuffisance cardiaque ou une surcharge volumique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes des peptides natriurétiques élevés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Essoufflement, fatigue, œdème et douleurs thoraciques peuvent être présents."
}
},
{
"@type": "Question",
"name": "Les peptides natriurétiques causent-ils des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont des biomarqueurs. Les symptômes proviennent de l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être plus subtils chez les personnes âgées, rendant le diagnostic difficile."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils différents chez les hommes et les femmes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes peuvent présenter des symptômes atypiques, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés aux peptides natriurétiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent l'œdème périphérique, la tachycardie et l'hypertension."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'insuffisance cardiaque liée aux peptides natriurétiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, contrôler la pression artérielle et éviter le tabac."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle les niveaux de peptides natriurétiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sodium peut augmenter la pression artérielle et les peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "L'exercice régulier aide-t-il à prévenir des niveaux élevés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier améliore la santé cardiaque et peut réduire les niveaux de peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il les peptides natriurétiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut aggraver les problèmes cardiaques et augmenter les niveaux de peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont basés sur les peptides natriurétiques ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les diurétiques, les inhibiteurs de l'ACE et les bêtabloquants."
}
},
{
"@type": "Question",
"name": "Les peptides natriurétiques sont-ils utilisés en thérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analogues de peptides natriurétiques sont utilisés pour traiter l'insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Comment les diurétiques agissent-ils sur les peptides natriurétiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les diurétiques réduisent le volume sanguin, ce qui peut diminuer les niveaux de peptides natriurétiques."
}
},
{
"@type": "Question",
"name": "Les traitements affectent-ils les niveaux de BNP ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement efficace peut réduire les niveaux de BNP, indiquant une amélioration."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure hypotension, déséquilibres électrolytiques et fatigue."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des niveaux élevés de BNP ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent l'insuffisance cardiaque, l'arythmie et l'hypertension."
}
},
{
"@type": "Question",
"name": "Les peptides natriurétiques sont-ils liés à des maladies rénales ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés peuvent indiquer une insuffisance rénale associée à des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment les complications cardiovasculaires se manifestent-elles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent se manifester par des douleurs thoraciques, des essoufflements et des syncopes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels facteurs aggravent les complications liées aux peptides natriurétiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension, le diabète et l'obésité aggravent les complications cardiaques et rénales."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'insuffisance cardiaque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hypertension, le diabète, l'obésité et les antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les niveaux de peptides natriurétiques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de maladies cardiaques et peut affecter les niveaux de peptides."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'insuffisance cardiaque augmente avec l'âge en raison de divers facteurs physiologiques."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il la santé cardiaque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "L'inactivité physique est-elle un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le manque d'exercice augmente le risque de maladies cardiovasculaires et d'insuffisance cardiaque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 13/02/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Clinical Biochemistry, Rigshospitalet University Hospital, Copenhagen, Denmark.
Publications dans "Peptides natriurétiques" :
3 publications dans cette catégorie
Affiliations :
Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. speranzadonatella.rubattu@uniroma1.it.
IRCCS Neuromed, Pozzilli, Isernia, Italy. speranzadonatella.rubattu@uniroma1.it.
Publications dans "Peptides natriurétiques" :
3 publications dans cette catégorie
Affiliations :
Cardiorenal Research Laboratory, Department of Cardiovascular Diseases, Department of Physiology and Bioengineering, College of Medicine Mayo Clinic, Rochester, MN, USA. Electronic address: burnett.john@mayo.edu.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center, Suita, Japan.
Omics Research Center, National Cerebral and Cardiovascular Center, Suita, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G).
Veterans Health Administration, Tennessee Valley Healthcare System, Clinical Sciences Research and Development, Nashville, TN (K.N.B.).
Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN (K.N.B.).
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (T.J.W.).
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Vanderbilt Translational and Clinical Cardiovascular Research Center, University Medical Center, Nashville, TN (H.F.-T., J.F.F., K.N.B., D.K.G).
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
IRCCS NEUROMED, 86077 Pozzilli, Italy.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Section of Neonatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Section of Neonatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Section of Neonatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 77030, USA. mohanv@bcm.edu.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Cardiovascular Medicine, Nara Medical University, Kashihara 634-8522, Nara, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Nara Prefecture Seiwa Medical Center, Mimuro 636-0802, Nara, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
2 publications dans cette catégorie
Affiliations :
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba 270-1694, Japan.
Publications dans "Peptides natriurétiques" :
The human complement system plays a crucial role in immune defense. However, its erroneous activation contributes to many serious inflammatory diseases. Since most unwanted complement effector functio...
An excessively activated or dysregulated complement system has been proven to be a vital contributor to the pathogenesis of periodontitis. It has been previously hypothesized that inhibiting the activ...
In our primary analysis, we used 26 independent 'cis' single nucleotide polymorphisms as IVs from the vicinity of the encoding locus of C5 that are associated with plasma C5 levels. In a secondary ana...
In our primary approach, inhibiting C5 reduced the risk of periodontitis (Odds ratio 0.89 per 1 standard deviation reduction in C5; 95% confidence Interval 0.80-0.98,...
The findings from our study suggest that C5 inhibition may reduce the risk of periodontitis, prioritizing C5 inhibitors as a potential adjunctive therapeutic intervention in this disease....
This study sought to understand the nature of the immune complexes that could be formed when a patient is exposed simultaneously to two different anti-complement component 5 (C5) antibodies, such as i...
The membrane attack complex (MAC or C5b-9) is an important effector of the immune system to kill invading microbes. MAC formation is initiated when complement enzymes on the bacterial surface convert ...
No reports have shown histological changes before and after anti-C5 monoclonal antibody treatment in patients with atypical hemolytic uremic syndrome (aHUS). Here, we report a rare case of complement-...
A 53-year-old woman developed aHUS with CFH gene mutation [c.3572C > T (p. Ser1191 Leu)] and anti-CFH antibodies. Her father had succumbed to acute kidney injury (AKI) in his 30 s. She exhibited AKI, ...
This is the first report showing the pathophysiology of aHUS in the kidneys and the efficacy of anti-C5 monoclonal antibody treatment by presenting serial kidney pathological features before and after...
The efficacy and safety of complement inhibition in COVID-19 patients is unclear....
A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO...
81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea...
Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...
The Phase 3 single-arm COMMODORE 3 study (ClinicalTrials.gov, NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor-naive patients with paroxysmal noctu...
The complement system is an essential component of our innate defense and plays a vital role in the pathogenesis of many diseases. Assessment of complement activation is critical in monitoring both di...
We performed a systematic analysis of the current methods used to assess complement components and reviewed whether the identified studies performed their complement measurements according to the reco...
A literature search using the Pubmed/MEDLINE database was performed focusing on studies measuring the key complement components C3, C5 and/or their split products and/or the soluble variant of the ter...
A total of 92 out of 376 studies were selected for full-text analysis. Forty-five studies (49%) were identified as using the correct sample type and techniques for their complement analyses, while 25 ...
A substantial part of the reviewed studies did not use the appropriate sample type for assessing complement activation or did not mention which sample type was used. This deviation from the standardiz...
Several patients with myasthenia gravis (MG) do not adequately respond to available drugs or exhibit poor tolerance, necessitating the need for new therapies....
The paper discusses the rapidly evolving target-specific immunotherapies that promise long-standing remissions in the management of MG. It is specifically focused on the role of complement, anti-compl...
Anti-AChR antibodies cause internalization of the receptors and activate complement leading to...
C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell-derived, and intracellular C3 plays critical roles in the immune response that i...